Stock TSHA TAYSHA GENE THERAPIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Real-time Estimate Cboe BZX
Other stock markets
 03:53:33 2024-05-06 pm EDT 		5-day change 1st Jan Change
2.585 USD +0.58% Intraday chart for Taysha Gene Therapies, Inc. +4.90% +45.20%
May. 02 Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome CI
Apr. 09 Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
AQ
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
AQ
Taysha Gene Therapies : March 2024 Corporate Presentation
PU
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
AQ
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
AQ
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies
PR
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
AQ
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
AQ
Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14
AQ
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
AQ
Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
AQ
Purcell & Lefkowitz LLP Is Investigating Taysha Gene Therapies, Inc. (NASDAQ: TSHA) for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TSHA Stock
  4. News Taysha Gene Therapies, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW